Team

Sean Kim, Ph.D., is the Vice President of Drug Metabolism and Pharmacokinetics (DMPK) at Recludix Pharma. Previously, he served as Vice President of Quantitative Pharmacology at IDRx, where he oversaw DMPK and Clinical Pharmacology activities spanning preclinical and clinical development. Before joining IDRx, Dr. Kim was Vice President of Nonclinical Development at Valo Health, leading teams in DMPK, M&S, Nonclinical Safety, CMC, and Clinical Pharmacology. Earlier in his career, Dr. Kim headed DMPK-Clinical Pharmacology group at Blueprint Medicines, where he played a key role in developing quantitative pharmacology strategies that supported the marketing authorization of Ayvakit™ and Gavreto™. Prior to that, he held positions of increasing responsibility in DMPK groups at Novartis and Bristol-Myers Squibb, following a career transition from his role as an investigative toxicologist at Wyeth. Dr. Kim earned his Ph.D. in Toxicology from Rutgers, The State University of New Jersey, and a B.S. in Biology from Sogang University.